General Electric Company

Sabic Innovative Plastics IP B.v.

Michael Todd Luttrell

Bruce Allan Hay

Brian Christopher Bales

Brian James Grimmond

Binil Itty Ipe Kandapallil

Daniel Eugene Meyer

Paul Dean Sybert

Gary William Yeager

James Edward Pickett

Slawomir Rubinsztajn

Hua Wang

Michael James Rishel

Joseph Anthony Suriano

Jon Michael Malinoski

Margaret Louise Blohm

Glen David Merfeld

Sumeet Jain

Rainer Koeniger

David Olson

Lawrence Charles Costa

Jeannette Christine DePuy

Christopher Michael Eastman

Jason Testa

Mary Elizabeth Spilker

David Cheney deMoulpied

Zhebo Ding

Jiang Ji

Bruce Allen Hay

David Allen Olson

The present application discloses nanoparticles, particularly nanoparticles of superparamagnetic iron oxide, which find utility in iron therapy and diagnostic imaging such as magnetic resonance (MR). The disclosed nanoparticles have been treated with an &#x3b1;-hydroxyphosphonic acid conjugate containing polyethylene glycol as a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are polyethylene oxide-based polymers and have a molecular weight greater than 5,000 dalton and less than or equal to about 30,000 daltons. Surprisingly, these nanoparticles have a more rapid and complete processing in liver of retained nanoparticles when compared to similar nanoparticles in which the PEG-based hydrophilic moiety has a molecular weight less than 5,000.

Superparamagnetic nanoparticles with PEG substituted &#x3b1;-hydroxy phosphonate shells

A method of sterilizing a nanoparticle preparation at a high temperature is provided. A plurality of nanoparticles are purified to form the preparation, wherein the nanoparticles comprise at least a core and a shell and the shell comprises one or more ligand species attached to the core. The nanoparticle preparation is made by a purified nanoparticle composition, a carrier fluid and an excess of the one or more ligand species not attached to the core. The ligand species attached to the core and the excess ligand species added after purification are structurally identical. The nanoparticle preparation provided by the present invention may be used as contrast agents in medical imaging techniques such as X-ray and magnetic resonance imaging.

Heat stable nanoparticle preparations and associated methods thereof

A nanoparticle composition is provided, wherein the composition comprises a nanoparticulate metal oxide; and a phosphorylated polyol comprising at least two phosphate groups. The polyol comprises one or more hydrophilic groups selected from the group consisting of polyethylene ether moieties, polypropylene ether moieties, polybutylene ether moieties, and combinations of two or more of the foregoing hydrophilic moieties. A method of making the nanoparticle composition is also provided. The nanoparticle compositions provided by the present invention may be used as contrast agents in medical imaging techniques such as X-ray and magnetic resonance imaging.

Nanoparticle composition and associated methods thereof

A diagnostic agent composition is provided which comprises a nanoparticle composition and a pharmaceutically acceptable carrier or excipient. The nanoparticle composition comprises a nanoparticulate metal oxide and a phosphorylated polyol, wherein the phosphorylated polyol comprises at least two phosphate groups and one or more hydrophilic groups selected from the group consisting of polyethylene ether moieties, polypropylene ether moieties, polybutylene ether moieties, and combinations of two or more of the foregoing hydrophilic moieties. The disclosure provides detailed guidance on methods of making and using such diagnostic agent compositions. The diagnostic agent compositions provided by the present invention are useful as contrast agents for medical diagnostic imaging techniques such as magnetic resonance (MR) imaging and X-ray imaging. The diagnostic agent composition may be administered to a subject via a variety of techniques, among them injection, inhalation, and ingestion.

Diagnostic agent composition and associated methods thereof

Improved methods for reducing boron concentration in seawater or brackish water, while simultaneously maintaining or improving the salt rejection of membrane and flow performance of polyamide reverse osmosis (RO) membranes include contacting the water with a composite membrane comprising moieties derived from an aromatic sulfonyl halide, a heteroaromatic sulfonyl halide, a sulfinyl halide; a sulfenyl halide; a sulfuryl halide; a phosphoryl halide; a phosphonyl halide; a phosphinyl halide; a thiophosphoryl halide; a thiophosphonyl halide, an isocyanate, a urea, a cyanate, an aromatic carbonyl halide, an epoxide or a mixture thereof.

Reverse osmosis composite membranes for boron removal

A thermosetting polymer material capable of being used in powder coatings. The thermosetting polymer material includes at least one hydroxyl functional aliphatic polycarbonates that is formulated and crosslinked with isocyanates to yield a thermoset organic coating material. These materials provide improved weatherability as compared to prior art powder coating materials while also being less expensive than prior art materials utilizing fluorinated polymers.

Aliphatic polycarbonates for use in thermosetting powder coatings

In one aspect, the present invention provides a contrast enhancement agent comprising an iron chelate having structure I wherein Ris independently at each occurrence a hydroxy group, a C-Chydroxyalkyl group, or a C-Calkyl group, and b is 0-4; R-Rare independently at each occurrence hydrogen, a C-Chydroxyalkyl group, or a C-Calkyl group, with the proviso that at least one of R-Ris a hydroxy group or a C-Chydroxyalkyl group; and wherein Q is a charge balancing counterion. Also provided is a metal chelating ligand having structure IX and medical formulations comprising the contrast enhancement I.

Hydroxylated contrast enhancement agents

Provided herein are chelator-functionalized nanoparticles comprising a passive core; and an active coating that demonstrate T1 magnetic resonance pattern upon exposure to a magnetic field. Also provided are methods of making such chelator-functionalized nanoparticles as well as imaging methods using the nanoparticles.

Chelator-functionalized nanoparticles

Growing community of inventors

Clifton Park, NY, United States of America

Michael Todd Luttrell